| Angioedemas, Hereditary
Berinert vs Kalbitor
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Berinert vs Kalbitor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKalbitor has a higher rate of injection site reactions vs Berinert based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kalbitor but not Berinert, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Berinert
Kalbitor
At A Glance
IV injection
C1 esterase inhibitor
SC injection
As needed
Plasma kallikrein inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 20 IU/kg body weight by slow intravenous injection; doses lower than 20 IU/kg body weight should not be administered.
Angioedemas, Hereditary 30 mg (3 mL) subcutaneously in three 10 mg (1 mL) injections per attack; an additional 30 mg may be administered within 24 hours if the attack persists.
Contraindications
- Life-threatening hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations
- Known clinical hypersensitivity to KALBITOR
Adverse Reactions
Most common (>4%) Dysgeusia
Serious Laryngeal edema, facial HAE attacks with laryngeal edema, swelling, exacerbation of hereditary angioedema, laryngospasm
Postmarketing Hypersensitivity/anaphylactic reactions, injection-site pain, injection-site redness, chills, fever, thromboembolism (including basilar artery thrombosis, pulmonary microemboli)
Most common (>=3%) Headache, nausea, diarrhea, pyrexia, injection site reactions, nasopharyngitis
Serious Hypersensitivity reactions including anaphylaxis
Postmarketing Similar adverse reactions as observed in clinical trials
Pharmacology
C1 esterase inhibitor is a plasma-derived serine protease inhibitor (serpin) that inhibits C1r, C1s, factor XIIa, kallikrein, and factor XIa, regulating the complement, contact (intrinsic coagulation), fibrinolytic, and coagulation cascades; IV replacement in C1-INH-deficient HAE patients suppresses bradykinin generation and reduces vascular permeability.
Plasma kallikrein inhibitor; ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein that blocks its binding site, reducing the conversion of HMW kininogen to bradykinin and thereby treating symptoms during acute episodic attacks of HAE.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Berinert
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Kalbitor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Berinert
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (3/8) · Qty limit (0/8)
Kalbitor
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Berinert
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Kalbitor
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BerinertView full Berinert profile
KalbitorView full Kalbitor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.